Literature DB >> 3089429

Managing Raynaud's phenomenon.

S Roath.   

Abstract

Mesh：

Year:  1986        PMID： 3089429      PMCID： PMC1340833          DOI： 10.1136/bmj.293.6539.88

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  11 in total

1.  Behavioral treatment of Raynaud's disease: long-term follow-up.

Authors:  R R Freedman; P Ianni; P Wenig
Journal:  J Consult Clin Psychol       Date:  1985-02

2.  Treatment of Raynaud's phenomenon with calcium channel blockers.

Authors:  C R Smith; R J Rodeheffer
Journal:  Am J Med       Date:  1985-02-22       Impact factor: 4.965

3.  Treatment of childhood Raynaud's disease by transdermal prostaglandin E2 analogue.

Authors:  D B Dunger; M J Dillon; C Daman-Willems; E D Cooke; S A Bowcock
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

4.  Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.

Authors:  O K Roald; E Seem
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

5.  Prostaglandin E1 vasospastic disease and thermography.

Authors:  V Kyle; G Parr; R Salisbury; P P Thomas; B Hazleman
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

6.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

7.  Use of biofeedback training in treatment of Raynaud's disease and phenomenon.

Authors:  D E Yocum; R Hodes; W R Sundstrom; C S Cleeland
Journal:  J Rheumatol       Date:  1985-02       Impact factor: 4.666

8.  Topical nitroglycerin ointment in Raynaud's phenomenon.

Authors:  M Fischer; B Reinhold; H Falck; M Török; K Alexander
Journal:  Z Kardiol       Date:  1985-05

9.  Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon.

Authors:  H Tindall; J E Tooke; V C Menys; M F Martin; J A Davies
Journal:  Eur J Clin Invest       Date:  1985-02       Impact factor: 4.686

10.  The treatment of severe Raynaud's phenomenon with verapamil.

Authors:  E L Kinney; G G Nicholas; J Gallo; C Pontoriero; R Zelis
Journal:  J Clin Pharmacol       Date:  1982-01       Impact factor: 3.126
View more
  3 in total

1.  The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.

Authors:  J Leppert; T Jonasson; H Nilsson; I Ringqvist
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 2.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

3.  Nisoldipine in primary Raynaud's phenomenon.

Authors:  V F Challenor; D G Waller; D A Francis; J L Francis; R Mani; S Roath
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.